{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T10:41:47Z","timestamp":1793788907543,"version":"4.6.1"},"reference-count":31,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T00:00:00Z","timestamp":1649203200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>We aimed to investigate French pharmacovigilance data. The objective was to characterize psoriatic conditions that occurred after beta\u2010blocker (BB) exposure and bring to light a possible pharmacovigilance signal.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Spontaneous reports of psoriatic conditions recorded in the French National Pharmacovigilance Database (FPVD) between 1985 and 2019 were extracted. We performed a retrospective, descriptive analysis of reports linked to BB exposure. Association between psoriasis risk and BB exposure was assessed using a case\/noncase study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Two hundred and twenty\u2010five reports of psoriatic conditions after BB exposure were recorded in the FPVD during the study period. Both cardioselective and noncardioselective, topical and systemic BBs are involved. Therapeutic indication of BB was mainly hypertension. Mean time to onset was 5\u00a0months and outcome was favourable in 68% after BB discontinuation. These features were concordant with those of literature reports. The reporting odds ratio (ROR) was 8.95 (95% confidence interval 7.75\u201010.33).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We highlighted a statistically significant disproportionality which constitutes a pharmacovigilance signal. Psoriasis risk with BBs is a class effect. Increasing surveillance during the first year of BB exposure is needed.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.15330","type":"journal-article","created":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T04:43:01Z","timestamp":1648615381000},"page":"3813-3818","source":"Crossref","is-referenced-by-count":12,"title":["Psoriasis risk after beta\u2010blocker exposure: Description of a pharmacovigilance signal"],"prefix":"10.1111","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4395-2445","authenticated-orcid":false,"given":"Brahim","family":"Azzouz","sequence":"first","affiliation":[{"name":"Regional Centre of Pharmacovigilance and Pharmacoepidemiology Reims University Hospital  Reims France"},{"name":"EA 3797 Vieillissement, Fragilit\u00e9, Faculty of Medicine University of Reims Champagne\u2010Ardenne  Reims France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apolline","family":"De Guizelin","sequence":"additional","affiliation":[{"name":"Regional Centre of Pharmacovigilance and Pharmacoepidemiology Reims University Hospital  Reims France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Lambert","sequence":"additional","affiliation":[{"name":"Regional Pharmacovigilance Centre Strasbourg University Hospital  Strasbourg France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Fresse","sequence":"additional","affiliation":[{"name":"Regional Pharmacovigilance Centre Nancy University Hospital  Nancy France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Morel","sequence":"additional","affiliation":[{"name":"Regional Centre of Pharmacovigilance and Pharmacoepidemiology Reims University Hospital  Reims France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5645-8366","authenticated-orcid":false,"given":"Thierry","family":"Trenque","sequence":"additional","affiliation":[{"name":"Regional Centre of Pharmacovigilance and Pharmacoepidemiology Reims University Hospital  Reims France"},{"name":"EA 3797 Vieillissement, Fragilit\u00e9, Faculty of Medicine University of Reims Champagne\u2010Ardenne  Reims France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,4,6]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13854"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200001030-00003"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090227"},{"issue":"1","key":"e_1_2_11_6_1","first-page":"32","article-title":"Drug\u2010provoked psoriasis: is it drug induced or drug aggravated?: understanding pathophysiology and clinical relevance","volume":"3","author":"Kim GK","year":"2010","journal-title":"J Clin Aesthetic Dermatol"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/PTT.S126727"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00204\u2010020\u201002870\u20108"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.recesp.2019.02.023"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.8964"},{"issue":"3","key":"e_1_2_11_11_1","first-page":"153","article-title":"Palmoplantar pustular psoriasis following initiation of a beta\u2010blocker: disease control with low\u2010dose methotrexate","volume":"94","author":"Stanford CW","year":"2014","journal-title":"Cutis"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102133.2008.08563.x"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199920020-00002"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2019.01.006"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-1809.1955.tb01348.x"},{"issue":"32","key":"e_1_2_11_16_1","first-page":"5","article-title":"Statistical methods in cancer research. Volume I \u2013 The analysis of case\u2010control studies","author":"Breslow NE","year":"1980","journal-title":"IARC Sci Publ"},{"issue":"4","key":"e_1_2_11_17_1","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel N","year":"1959","journal-title":"J Natl Cancer Inst"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41581\u2010019\u20100244\u20102"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477\u20107525\u20104\u201035"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2014.1019"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629050-00003"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1978.tb01479.x"},{"issue":"1","key":"e_1_2_11_23_1","first-page":"95","article-title":"Psoriasiform eruption induced by propranolol","volume":"24","author":"Halevy S","year":"1979","journal-title":"Cutis"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.39688"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/00015550510032823"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1159\/000111509"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.9957"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31819a4b7c"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2014.2452"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2020.05.013"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2018.1508446"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010019\u201000865\u20108"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15330","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.15330","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15330","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T05:01:03Z","timestamp":1692680463000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.15330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,6]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1111\/bcp.15330"],"URL":"https:\/\/doi.org\/10.1111\/bcp.15330","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,6]]}}}